Today Promore announced that 50% of the patients in the phase IIb HEAL LL-37 trial have been included and expects full patient enrollment in early 2020, which we believe makes it possible to deliver top-line results in H1 2020. Despite a tiny organization, Promore shows it can deliver according to the time plan, which is confidence-enhancing ahead of the upcoming phase III study with PXL01.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se